Literature DB >> 24593907

Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease.

Rahul Srinivasan1, Brandon J Henderson2, Henry A Lester2, Christopher I Richards3.   

Abstract

Chronic exposure to nicotine results in an upregulation of neuronal nicotinic acetylcholine receptors (nAChRs) at the cellular plasma membrane. nAChR upregulation occurs via nicotine-mediated pharmacological receptor chaperoning and is thought to contribute to the addictive properties of tobacco as well as relapse following smoking cessation. At the subcellular level, pharmacological chaperoning by nicotine and nicotinic ligands causes profound changes in the structure and function of the endoplasmic reticulum (ER), ER exit sites, the Golgi apparatus and secretory vesicles of cells. Chaperoning-induced changes in cell physiology exert an overall inhibitory effect on the ER stress/unfolded protein response. Cell autonomous factors such as the repertoire of nAChR subtypes expressed by neurons and the pharmacological properties of nicotinic ligands (full or partial agonist versus competitive antagonist) govern the efficiency of receptor chaperoning and upregulation. Together, these findings are beginning to pave the way for developing pharmacological chaperones to treat Parkinson's disease and nicotine addiction.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COPI; COPII; Chaperoning; Confocal; Dopaminergic; ER exit sites; Endoplasmic reticulum stress; FRET; Golgi; Ligand; Neurodegeneration; Neuroprotection; Nicotine; Parkinson's disease; Pharmacological chaperone; TIRF; Tobacco; Unfolded protein response; nAChR

Mesh:

Substances:

Year:  2014        PMID: 24593907      PMCID: PMC6075820          DOI: 10.1016/j.phrs.2014.02.005

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  117 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Activation of the unfolded protein response in Parkinson's disease.

Authors:  J J M Hoozemans; E S van Haastert; P Eikelenboom; R A I de Vos; J M Rozemuller; W Scheper
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

3.  Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response.

Authors:  Rahul Srinivasan; Christopher I Richards; Cheng Xiao; Doreen Rhee; Rigo Pantoja; Dennis A Dougherty; Julie M Miwa; Henry A Lester
Journal:  Mol Pharmacol       Date:  2012-02-29       Impact factor: 4.436

4.  Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.

Authors:  M E Benwell; D J Balfour; J M Anderson
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

5.  Identification of sequence motifs that target neuronal nicotinic receptors to dendrites and axons.

Authors:  Jian Xu; Yongling Zhu; Stephen F Heinemann
Journal:  J Neurosci       Date:  2006-09-20       Impact factor: 6.167

Review 6.  Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery.

Authors:  Henry A Lester; Cheng Xiao; Rahul Srinivasan; Cagdas D Son; Julie Miwa; Rigo Pantoja; Matthew R Banghart; Dennis A Dougherty; Alison M Goate; Jen C Wang
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

7.  Chronic high dose transdermal nicotine in Parkinson's disease: an open trial.

Authors:  G Villafane; P Cesaro; A Rialland; S Baloul; S Azimi; C Bourdet; J Le Houezec; I Macquin-Mavier; P Maison
Journal:  Eur J Neurol       Date:  2007-10-17       Impact factor: 6.089

Review 8.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

Review 9.  Molecular chaperones and photoreceptor function.

Authors:  Maria Kosmaoglou; Nele Schwarz; John S Bett; Michael E Cheetham
Journal:  Prog Retin Eye Res       Date:  2008-03-29       Impact factor: 21.198

10.  Inter-Golgi transport mediated by COPI-containing vesicles carrying small cargoes.

Authors:  Patrina A Pellett; Felix Dietrich; Jörg Bewersdorf; James E Rothman; Grégory Lavieu
Journal:  Elife       Date:  2013-10-01       Impact factor: 8.140

View more
  27 in total

1.  The nicotine metabolite, cotinine, alters the assembly and trafficking of a subset of nicotinic acetylcholine receptors.

Authors:  Ashley M Fox; Faruk H Moonschi; Christopher I Richards
Journal:  J Biol Chem       Date:  2015-08-12       Impact factor: 5.157

Review 2.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

3.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

Review 4.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

5.  Nicotinic receptor subtype-selective circuit patterns in the subthalamic nucleus.

Authors:  Cheng Xiao; Julie M Miwa; Brandon J Henderson; Ying Wang; Purnima Deshpande; Sheri L McKinney; Henry A Lester
Journal:  J Neurosci       Date:  2015-03-04       Impact factor: 6.167

Review 6.  Proteins and chemical chaperones involved in neuronal nicotinic receptor expression and function: an update.

Authors:  Arianna Crespi; Sara Francesca Colombo; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2017-04-19       Impact factor: 8.739

7.  Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.

Authors:  T Bordia; M McGregor; J M McIntosh; R M Drenan; M Quik
Journal:  Neuroscience       Date:  2015-03-24       Impact factor: 3.590

8.  Structurally distinct ligands rescue biogenesis defects of the KATP channel complex via a converging mechanism.

Authors:  Prasanna K Devaraneni; Gregory M Martin; Erik M Olson; Qing Zhou; Show-Ling Shyng
Journal:  J Biol Chem       Date:  2015-01-30       Impact factor: 5.157

9.  Functional Consequences of CHRNA7 Copy-Number Alterations in Induced Pluripotent Stem Cells and Neural Progenitor Cells.

Authors:  Madelyn A Gillentine; Jiani Yin; Aleksandar Bajic; Ping Zhang; Steven Cummock; Jean J Kim; Christian P Schaaf
Journal:  Am J Hum Genet       Date:  2017-11-09       Impact factor: 11.025

10.  A Novel α2/α4 Subtype-selective Positive Allosteric Modulator of Nicotinic Acetylcholine Receptors Acting from the C-tail of an α Subunit.

Authors:  Jingyi Wang; Alexander Kuryatov; Zhuang Jin; Jack Norleans; Theodore M Kamenecka; Paul J Kenny; Jon Lindstrom
Journal:  J Biol Chem       Date:  2015-10-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.